In January 1896, a pivotal moment in medical history occurred in a small lamp factory in Chicago. Rose Lee, a middle-aged woman with a breast tumor, underwent experimental treatment using an X-ray tube.
This event marked the birth of radiotherapy, ushering in a new era in cancer treatment.
Since then, radiation therapy has evolved significantly. The discovery of radium and other radioactive elements allowed higher doses of radiation to target deeper-seated cancers. Proton therapy further improved precision, minimizing damage to surrounding healthy tissue. Advances in medical physics, computer technology, and imaging techniques have continually improved this approach.
The turn of the millennium introduced targeted radiopharmaceuticals, which act like heat-seeking missiles that deliver radioactive warheads directly to tumors via the bloodstream. Although only a few such therapies are currently available for prostate cancer and some neuroendocrine tumors, investment in this technology is growing rapidly.
AstraZeneca recently acquired Fusion Pharmaceuticals for $2.4 billion, joining other major pharmaceutical companies such as Bristol Myers Squibb, Eli Lilly and Novartis in the radiopharmaceutical space. This surge in interest highlights the potential of these therapies to offer a fundamentally different approach to cancer treatment.
Challenges and innovations
Despite the promise, the development and delivery of radiopharmaceuticals comes with unique challenges, including manufacturing and delivery time before the radioactivity decays. Expanding these therapies to a broader group of cancers requires the discovery of new tumor-targeting particles and suitable targets.
Historically, the only widely used radiopharmaceutical was a radioactive form of iodine to treat thyroid cancer. However, other cancers lacked a similar natural affinity for radioactive elements, necessitating the design of drugs capable of targeting specific tumor proteins.
Initial radiopharmaceuticals were used for imaging, but the potential for therapeutic applications quickly became apparent. Early efforts in the late 1990s and early 2000s met with limited success, but continued efforts, particularly in academic settings, eventually led to breakthroughs.
Researchers at Weill Cornell Medicine and European clinics pioneered the development of radiolabeled agents that target prostate-specific membrane antigen (PSMA) and somatostatin receptors, respectively. These efforts culminated in the approval of Lutathera in 2017, a drug that targets neuroendocrine tumors, and later, Pluvicto for prostate cancer in 2022.
Alpha vs Beta Emitters
Pluvicto and Lutathera, both built around peptides that bind to cancer cell receptors and deliver radiation, primarily use beta isotopes. These isotopes emit high-energy electrons that penetrate tumors and surrounding cells, causing DNA damage and cell death. Gamma rays, produced in smaller amounts, help track the drug's distribution.
Current research is increasingly focusing on alpha-emitting isotopes, which provide more powerful and localized cell destruction. Alpha particles, larger and more energetic than beta particles, can effectively target tumor cells while sparing nearby healthy tissue. This precision has spurred interest from companies such as Convergent Therapeutics and Fusion Pharmaceuticals.
Future directions
The development of new radiopharmaceuticals involves identifying cancer-selective proteins and expanding manufacturing capabilities. Novartis, a leader in this field, is working on drugs that target different proteins and is building new manufacturing facilities. The logistics of manufacturing and distributing these therapies are complex, requiring meticulous coordination to ensure timely delivery while maintaining potency.
The industry's renewed interest in radiopharmaceuticals promises new treatment options, bridging historical innovations with future advances. With continued investment and research, radiopharmaceuticals have the potential to revolutionize cancer treatment, offering precision and effectiveness in targeting malignant tumors.
edition
t7 live
